Welcome to our dedicated page for Sight Sciences news (Ticker: SGHT), a resource for investors and traders seeking the latest updates and insights on Sight Sciences stock.
Sight Sciences, Inc. (SGHT) pioneers transformative ophthalmic devices for glaucoma and dry eye treatment, merging surgical precision with evidence-based therapeutic solutions. This page serves as the definitive source for SGHT-related news, offering stakeholders timely updates on advancements shaping eye care innovation.
Access press releases, clinical trial results, and regulatory milestones covering minimally invasive glaucoma surgery (MIGS) technologies like the OMNI Surgical System and the TearCare System for dry eye management. Our curated collection ensures professionals and investors stay informed about product approvals, peer-reviewed research, and strategic partnerships driving the company’s growth.
Explore updates across key areas including surgical device innovations, real-world clinical data, and regulatory filings. Each announcement is vetted for relevance, providing actionable insights into SGHT’s market position and technological leadership in interventional eyecare.
Bookmark this page for streamlined access to Sight Sciences’ latest developments. Regularly updated with authoritative content, it empowers users to track progress in ophthalmic treatment solutions backed by clinical validation and engineering excellence.
Sight Sciences (NASDAQ: SGHT) reported three peer‑reviewed publications (Nov 1–Nov 11, 2025) showing the OMNI surgical system with TruSync technology lowers intraocular pressure (IOP) and medication use in cataract-combination and standalone glaucoma procedures, including analyses in African American patients.
Key results: a 24‑month prospective cohort (n=18) showed mean IOP 26.1 mmHg reduced by 9.7 mmHg at 12 months and 10.6 mmHg at 24 months, medications fell from 1.8 to 0.5 by 24 months, with two‑thirds medication‑free at Month 24. A ~13,000‑eye IRIS registry analysis found the highest ≥20% IOP reduction rate with OMNI among MIGS devices. A 220‑eye subgroup showed IOP reduction up to 3 years regardless of lens status or severity.
Sight Sciences (Nasdaq: SGHT) reported Q3 2025 results and raised full‑year guidance on Nov 6, 2025. Q3 revenue was $19.9M (‑1% YoY) with Surgical Glaucoma revenue of $19.7M (+6% YoY) and Dry Eye revenue of $0.2M (‑88% YoY). Gross profit was $17.2M and gross margin improved to 86%. Q3 adjusted operating expenses fell to $19.8M (‑17% YoY) and GAAP operating expenses were $25.1M, which included $2.8M of restructuring charges.
The company raised 2025 revenue guidance to $76.0M–$78.0M and cut adjusted operating expense guidance to $90M–$92M. Cash was $92.4M and long‑term debt $40.0M as of Sept 30, 2025.
Sight Sciences (Nasdaq: SGHT) announced the appointments of Alison (Ali) Bauerlein as Chief Operating Officer and James (Jim) Rodberg as Chief Financial Officer, effective November 5, 2025.
The company said the new COO role will support scaling reimbursed interventional dry eye and MIGS commercial efforts. Bauerlein joins the executive team after serving as Sight Sciences CFO since April 2023 and previously helped scale Inogen to over $350 million in annual sales. Rodberg was promoted from VP of Finance and corporate controller, has 20 years of finance and accounting experience and served as interim CFO in 2023.
The board also reported that Erica Rogers (six years) and Brenda Becker (three years) have stepped down from the board.
Sight Sciences (Nasdaq: SGHT) will present at two investor conferences in New York in November and December 2025. Management will present at the Stifel 2025 Healthcare Conference on Tuesday, November 11, 2025 at 8:20 AM PT / 11:20 AM ET and at the Piper Sandler 37th Annual Healthcare Conference on Tuesday, December 2, 2025 at 5:30 AM PT / 8:30 AM ET. Interested parties can access a live and archived webcast of each fireside chat via the company’s Investors website at https://investors.sightsciences.com/.
Sight Sciences (Nasdaq: SGHT) will report third quarter 2025 financial results for the period ended September 30, 2025 after market close on Thursday, November 6, 2025.
Management will discuss results on a conference call at 1:30 p.m. PT / 4:30 p.m. ET. Investors can access a live and archived webcast on the company website at www.sightsciences.com under the Investors & News & Events section. The webcast replay will be available for at least 90 days after the event.
Sight Sciences (Nasdaq: SGHT) announced that two Medicare Administrative Contractors, Novitas Solutions and First Coast Service Options, established jurisdiction-wide pricing for CPT 0563T (TearCare procedure) effective for dates of service on or after January 1, 2025.
The two MACs cover an estimated 10.4 million covered lives, representing approximately 30% of Medicare fee-for-service enrollees in their jurisdictions. Claims will be payable based on individual medical necessity determinations and local fee schedules will be published on the MACs' websites.
The company also launched a Sight Access Portal to assist providers with benefit verifications and reimbursement, and said it will provide updated 2025 revenue and adjusted operating expenses guidance during its Q3 2025 earnings call.
Sight Sciences (NASDAQ:SGHT) announced the publication of a comprehensive meta-analysis in the European Journal of Ophthalmology demonstrating the long-term effectiveness of its OMNI® Surgical System for glaucoma treatment. The study, analyzing 29 publications covering 2,379 eyes, showed that 89% of patients achieved treatment success with IOP reduction ≥20% from baseline after 6-24 months.
Key findings revealed that 66-68% of patients remained medication-free after treatment, with significant IOP reductions maintained at 24 months. The system demonstrated cost-effectiveness compared to iStent inject®, with higher quality-adjusted life years (QALYs) of 8.95 over a lifetime horizon versus 8.93 for iStent inject.
Sight Sciences (NASDAQ:SGHT) announced that UnitedHealthcare (UHC) will include its OMNI® Surgical System in its expanded coverage policy for glaucoma surgical treatments, effective October 1, 2025. The coverage applies to UHC's commercial and individual exchange benefit plans, reaching approximately 30 million of UHC's over 50 million total covered lives.
The policy covers procedures including goniotomy, trabeculotomy, canaloplasty, and combined procedures for adults with mild to moderate open-angle glaucoma. The FDA-cleared OMNI Surgical System is indicated for canaloplasty followed by trabeculotomy to reduce intraocular pressure in adult patients with primary open angle glaucoma, and can be performed before, during, or after cataract surgery.
Sight Sciences (NASDAQ:SGHT) announced that its TearCare System has been included in the prestigious TFOS DEWS III report published in the American Journal of Ophthalmology. This recognition represents significant validation for TearCare's clinical efficacy in treating dry eye disease (DED) and meibomian gland disease (MGD).
The report highlights multiple clinical studies supporting TearCare's effectiveness, including the SAHARA trial, which demonstrated clinical superiority over Restasis in improving Tear Breakup Time and gland function, and the OLYMPIA trial, which showed significant improvement in DED symptoms, particularly in severe cases compared to LipiFlow.
Sight Sciences (Nasdaq: SGHT), an eyecare technology company, announced its participation in the Morgan Stanley Global Healthcare Conference in New York. The company's management will deliver a presentation on Wednesday, September 10, 2025, at 10:50 am PT / 1:50 pm ET.
Investors and interested parties can access both the live and archived versions of the fireside chat through the "Investors" section on the company's website at investors.sightsciences.com.
FAQ
What is the current stock price of Sight Sciences (SGHT)?
What is the market cap of Sight Sciences (SGHT)?
